Libeled: 8-21-61, 8-29-61, and 8-30-61, Dist. Mass.

CHARGE: 501(c)—when shipped, the strength of the article differed from that which it purported to possess; 502(a)—the label statement "4-nitrophenyl-arsonic acid (Histostat) 0.025%" was false and misleading as applied to a product which contained more than the declared amount of this ingredient; and 502(j)—the article was dangerous to the health of turkeys when used in the dosage, or with the frequency or duration prescribed, recommended, or suggested in the labeling.

Disposition: 2-16-62. Consent—claimed by Elmore Milling Co., Inc., and released under bond to be brought into compliance with the law.

NEW DRUGS SHIPPED WITHOUT EFFECTIVE APPLICATION

DRUGS FOR HUMAN USE

6904. Vitamin B₁₂-B₁, Elixir Vinivita, and Expectogen. (F.D.C. No. 46942. S. Nos. 37-804/6 T.)

QUANTITY: 16 btls. of Vitamin B_{12} - B_{1} , 151 1-pt. btls. of Elixir Vinivita, and 203 1-pt. btls. of Expectogen, at Montgomery, Ala.

SHIPPED: Between 2-27-61 and 9-26-61, from St. Louis, Mo., by E. W. Heun Co.

Label In Part: (Btl.) "Vitamin B₁₂-B₁ Each 5 cc. (1 teaspoonful) contains: Vitamin B-12, N.F. 25 mcg. Vitamin B-1 U.S.P. 10 mg. Manufactured for King Pharmaceutical Co., Inc., Montgomery 3, Alabama."; "King's One Pint Elixir Vinivita Improved Each 5 cc. (1 teaspoonful) contains: * * * Distributed by King Pharmaceutical Co., Inc., Montgomery, Alabama * * * Caution: Federal law prohibits dispensing without a prescription."; and "King's One Pint Expectogen For Relief of Coughs Due to Colds Each Fluid Ounce Represents: Dextromethorphan Hydrobromide 60 mg. Chlorpheniramine Maleate 12 mg. Potassium Guaiacol Sulfonate 8 gr. Ammonium Chloride 8 gr. Tartar Emetic ½ gr. Chloroform 2 min. * * * Distributed by King Pharmaceutical Co., Inc., Montgomery, Alabama. Dosage: Adults, orally 1 or 2 teaspoonsful every four hours as required. Children 6-12 years, one-half adult dose. For younger children consult physician."

Libeled: 1-29-62, M. Dist. Ala.

CHARGE: (Vitamin B_{12} - B_1), 502(a)—when shipped, the bottle label contained false and misleading representations that the article was adequate and effective for promoting growth and appetite in a child who does not eat adequately or well; as an adjunct in treating the chronically ill or undernourished child; as a nutritional supplement in chronic diarrhea and celiac diseases; and for shortening convalescence through increasing the appetite; (Elixir Vinivita), 502(a)—the bottle label contained false and misleading representations that the article was adequate and effective as a treatment for or preventive of chronic fatigue, poor appetite, and iron and vitamin deficiencies; 503(b)(4)—the article was not subject to the provisions of 503(b)(1) and its label bore the statement "Caution: Federal law prohibits dispensing without prescription"; and (Expectogen), 505(a)—the article was a new drug which may not be introduced into interstate commerce since an application filed pursuant to law was not effective with respect to such drug.

Disposition: 2-2-62. Consent—destruction.